CDK 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (mBC): The Likelihood of being Helped or Harmed (LHH) as a patient-centred tool to assess clinical impact and safety

被引：0

作者：

Mastrantoni, L. ^{[1
]}

Orlandi, A. ^{[2
]}

Palazzo, A. ^{[2
]}

Garufi, G. ^{[1
]}

Fabi, A. ^{[3
]}

Daniele, G. ^{[4
]}

Giannarelli, D. ^{[5
]}

Tortora, G. ^{[6
]}

Bria, E. ^{[6
]}

机构：

[1] Univ Cattolica Sacro Cuore, Med Oncol Dept, Rome, Italy

[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy

[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Women Children & Publ Hlth Sci, Precis Med Breast Unit, Sci Directorate, Rome, Italy

[4] Fdn Policlin Univ Agostino Gemelli IRCCS, UOC Phase I, Rome, Italy

[5] Fdn Policlin Univ Agostino Gemelli IRCCS, Biostat, Rome, Italy

[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Unit, Rome, Italy

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.273

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

234P

引用

页码：S644 / S644

页数：1

共 50 条

[31] The role of CDK4/6 inhibitors in early breast cancer
Gil-Gil, Miguel
Alba, Emilio
Gavila, Joaquin
de la Haba-Rodriguez, Juan
Ciruelos, Eva
Tolosa, Pablo
Candini, Daniele
Llombart-Cussac, Antonio
BREAST, 2021, 58 : 160 - 169
[32] Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer
Visani, L.
Becherini, C.
Scoccimarro, E.
Valzano, M.
Saieva, C.
Ratosa, I.
Ribnikar, D.
Orazem, M.
Marinko, T.
Desideri, I.
Scotti, V.
Morandi, A.
Lambertini, M.
Meattini, I.
Livi, L.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S643 - S643
[33] Real-world (RW) utilization and patient outcomes across three CDK4/6 inhibitors in metastatic breast cancer (mBC)
Weipert, Caroline
Wander, Seth
Davis, Andrew
Bucheit, Leslie
Saha, Jayati
Liao, Jiemin
Zhang, Nicole
Stover, Daniel
Bardia, Aditya
Cristofanilli, Massimo
CANCER RESEARCH, 2024, 84 (09)
[34] CDK4/6 inhibitors in breast cancer: spotting the difference
Jose Manuel Perez-Garcia
Javier Cortes
Antonio Llombart-Cussac
Nature Medicine, 2021, 27 : 1868 - 1869
[35] Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer
Visani, Luca
Livi, Lorenzo
Ratosa, Ivica
Orazem, Miha
Ribnikar, Domen
Saieva, Calogero
Becherini, Carlotta
Salvestrini, Viola
Scoccimarro, Erika
Valzano, Marianna
Cerbai, Cecilia
Desideri, Isacco
Bernini, Marco
Orzalesi, Lorenzo
Nori, Jacopo
Bianchi, Simonetta
Morandi, Andrea
Meattini, Icro
RADIOTHERAPY AND ONCOLOGY, 2022, 177 : 40 - 45
[36] Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature
Franco, Rejane
Cao, Jeffrey Q.
Yassa, Michael
Hijal, Tarek
CURRENT ONCOLOGY, 2023, 30 (06) : 5485 - 5496
[37] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
Martin, Miguel
Garcia-Saenz, Jose A.
Manso, Luis
Llombart, Antonio
Cassinello, Alejo
Atienza, Manuel
Ringeisen, Francois
Ciruelos, Eva
FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
[38] BIOMARKERS RELATED TO SURVIVAL BENEFIT IN THE TREATMENT OF METASTATIC LUMINAL BREAST CANCER (mBC) WITH CYCLIN 4/6 INHIBITORS (CDK 4/6i) PLUS ENDOCRINE THERAPY (ET)
Murillo, Serafin Morales
Cudos, Ariadna Gasol
Der-Abrain, Noemi Tuset
Urdanibia, Izaskun
Galindo, Alvaro Rodriguez
Sanchez, Ana Velasco
Villellas, Felip Vilardell
Guzman, Douglas Sanchez
Morales, Carles Canosa
Olive, Jordi Mele
Cid, Laura Arbones
CANCER RESEARCH, 2023, 83 (05)
[39] First clinical experience with CDK4/6 inhibitors in breast cancer therapy
Cobec, Ionut Marcel
Moleriu, Lavinia
Moatar, Aurica Elisabeta
Rempen, Andreas
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (05)
[40] Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Barroso-Sousa, Romualdo
Shapiro, Geoffrey I.
Tolaney, Sara M.
BREAST CARE, 2016, 11 (03) : 167 - 173

← 1 2 3 4 5 →